Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
about
The relationship between self-reported and registry-based data on use of psychoactive medications in postmenopausal women.Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan.Validation of a method for identifying nursing home admissions using administrative claims.Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community.Osteoporosis quality indicators using healthcare utilization data.Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data.Self-reported responsiveness to direct-to-consumer drug advertising and medication use: results of a national survey.An electronic health record driven algorithm to identify incident antidepressant medication users.Implications of the accuracy of MEPS prescription drug data for health services research.Agreement between self-report and prescription data in medical records for pregnant women.Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).Measuring and improving adherence to osteoporosis pharmacotherapy.Role of Health Literacy in Self-Reported Musculoskeletal Disorders.Validity of self-report of lipid medication use: the Atherosclerosis Risk in Communities (ARIC) Study.Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.Agreement and validity of electronic health record prescribing data relative to pharmacy claims data: A validation study from a US electronic health record database.Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures.Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users.Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry.Obesity is not protective against fracture in postmenopausal women: GLOWThe Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design.RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reductionAgreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use.Metabolic profiling and population screening of analgesic usage in nuclear magnetic resonance spectroscopy-based large-scale epidemiologic studies.Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women.Use of calcium supplements, vitamin D supplements and specific osteoporosis drugs among French women aged 75-85 years: patterns of use and associated factors.Self-perception of fracture risk: what can it tell us?Validity of Self-Reported Medication Use Compared With Pharmacy Records in a Cohort of Older Women: Findings From the Women's Health InitiativeAdherence to osteoporosis medications amongst Singaporean patients.Evaluation of a program of integrated care to reduce recurrent osteoporotic fractures.
P2860
Q30652694-1C97CF2C-23D5-4359-8B50-CC267494CA4CQ30873785-BA641DE2-C7C8-4B41-87DE-EA0F48B1CFA4Q33309498-B108D6BA-789B-42E3-A290-4608363E62B0Q33552640-8D7E201E-40D3-4223-AC2B-2D0A0E81A87BQ33616400-B9DA0D26-C472-470A-9634-2674996334C0Q33829782-73B468B7-CCCD-465F-BABF-A8A48E2CED55Q34028846-6653DA29-BFB3-4F71-B4F9-C95A56E2439BQ34100018-16E83F44-F609-4493-AE63-D9530DD0CD75Q34123997-2C253428-6D4F-44A5-BB44-E2AC6DB03312Q34130041-F20581BC-A8A3-45E5-96A2-DF6283C41B20Q35077750-A727D80A-CFCA-4426-ABFE-462285459659Q35177690-2F141232-994C-4771-8FBF-CB4F34124886Q36015225-87D96FA7-6764-43B9-8913-8ADA748B73D7Q36075326-216A7CA6-D8C0-4F5C-861F-45A6ED7F08BFQ36378748-6E8BA3A6-ACC1-4450-84E0-F568896D0796Q36400213-AF2B9064-EAA7-42C7-8C81-445B5817013FQ36547005-16196538-A0E4-4C13-8A5E-B8E303077A80Q36952131-900927C9-08AC-48BB-8BBB-1ADB0A98A0DBQ36952170-2406DF18-6A13-492D-BEB7-F71B81523678Q36963533-73625BF2-FCAB-4C55-94A0-B5E281CB3F83Q36980595-FE840DAE-AE8D-4FC6-AEF3-044A1DD2C86CQ37213380-42C51D08-F6F7-4250-89CC-A497A207FFEEQ37264078-553AF272-FDC4-4DB4-8D86-50FB6D5C01DBQ37291832-3CFD1714-770F-4AF1-82A1-BF6B9E2C3E04Q37304218-BA46530E-6FAB-4C2B-B056-82275969B9B1Q37640455-21EFCFA9-47ED-4F84-92B9-38DCDB4BE771Q38151572-D32D7BDD-8F23-4E1D-9E36-250256F2BD07Q38598416-6A8EFBB6-AD1F-4D39-9CB4-3EBB1780DF5CQ39611541-074248F8-D2B3-4EDB-94EC-6CE5D299ECD7Q44541046-62F5E7B7-CB37-44CF-85FF-A4C213B22FBFQ46356238-E9987AB3-7EBB-47C4-B453-B964D52378E5
P2860
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Agreement and validity of phar ...... chronic glucocorticoid users.
@ast
Agreement and validity of phar ...... chronic glucocorticoid users.
@en
type
label
Agreement and validity of phar ...... chronic glucocorticoid users.
@ast
Agreement and validity of phar ...... chronic glucocorticoid users.
@en
prefLabel
Agreement and validity of phar ...... chronic glucocorticoid users.
@ast
Agreement and validity of phar ...... chronic glucocorticoid users.
@en
P2093
P356
P1476
Agreement and validity of phar ...... chronic glucocorticoid users.
@en
P2093
Allison Freeman
Jeffrey R Curtis
Kenneth G Saag
Stacey H Kovac
P304
P356
10.1002/PDS.1226
P577
2006-10-01T00:00:00Z